This compound serves as a key intermediate in the synthesis of antiviral nucleoside analogs, particularly for the treatment of hepatitis B infection. It is utilized in the production of agents that act by competing with natural substrates for incorporation into viral DNA, thereby inhibiting viral DNA synthesis and leading to chain termination. The resulting pharmaceuticals are effective in reducing viral load and form part of long-term management strategies for chronic hepatitis B. These final compounds demonstrate selectivity for viral polymerase, which minimizes host DNA damage and supports a favorable safety profile.